| Price | $1.88 |
| Year Range | $1.77 – $14.85 |
| Market Cap | $50M |
| PE Ratio | 5.75 |
| Industry | Biotechnology |
What Is Elicio Therapeutics’s AI Stock Analysis?
Elicio Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Elicio Therapeutics’s momentum in near-real time.
Elicio Therapeutics (ELTX) has an AltIndex AI Score of 36/100, currently a Sell signal. The AI Score distills Elicio Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Elicio Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Elicio Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving ELTX’s AI Score?
Fundamentals
Net income for the last quarter was $-8.2M. This is an increase of -30.50% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -22.19%, suggesting positive year-over-year growth. Ebitda for the last quarter was $-13M. This represents a decrease of 16.05% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 28.03%, which may be a cause for concern. The current P/E ratio is 5.75. This may be considered low, potentially indicating undervaluation and a bullish outlook.
See Elicio Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $1.88. This represents a decrease of 8.29% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 82.35%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $1.89, which is lower than the previous SMA10 of $1.89. This suggests a potential downward trend in price movement. The RSI is 31.4, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at Elicio Therapeutics is low (an estimate of only 27% of employees have a positive outlook), a concerning sign. Elicio Therapeutics has an estimate of 6,000 visitors to their webpage, with no meaningful increase or decrese in the last couple of months.
Explore Elicio Therapeutics’s job postings, web traffic and app downloads.
Sentiment & social
Elicio Therapeutics has 450 followers on their Twitter page. The number of followers is up by 3% in the last couple of months, indicating an increased interest in the company.
Track Elicio Therapeutics’s market sentiment.
Frequently Asked Questions: Elicio Therapeutics AI Stock Analysis
Elicio Therapeutics's AltIndex AI Score is 36/100, currently a Sell signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Elicio Therapeutics a Sell (36/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Elicio Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the ELTX AI Score or sign up to read the full thesis.
